SCHEMBL1852588

SCHEMBL1852588

CCOC(=O)c1cccc(-c2cccc3nn(Cc4cccc(Cl)c4)cc23)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR52 Q9Y2T5 1/20 0.53
KLKB1 P03952 1/20 0.49
TP53 P04637 2/20 0.47
SMN1; SMN2 Q16637 4/20 0.47
KMT2A Q03164 2/20 0.47
HPGD P15428 2/20 0.47
LMNA P02545 2/20 0.47
MEN1 O00255 1/20 0.47
ALDH1A1 P00352 2/20 0.45
KDM4E B2RXH2 1/20 0.45
JMJD6 Q6NYC1 2/20 0.44
ELANE P08246 1/20 0.43
ADORA3 P0DMS8 1/20 0.42
ADORA2B P29275 1/20 0.42
GABRA2 P47869 1/20 0.41
GABRB2 P47870 1/20 0.41
MAOB P27338 1/20 0.41
NPC1 O15118 1/20 0.41
MAPT P10636 1/20 0.41
RAB9A P51151 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1856096 0.92 GPR52 (0.54) GPR52SMN1; SMN2KMT2ALMNAALDH1A1
SCHEMBL1851680 0.90 GPR52 (0.51) GPR52SMN1; SMN2KMT2ALMNAALDH1A1
SCHEMBL3217768 0.89 GPR52 (0.50) GPR52KLKB1TP53JMJD6MAPT
SCHEMBL1853574 0.89 GPR52 (0.48) GPR52KLKB1TP53SMN1; SMN2ALDH1A1
SCHEMBL3215484 0.89 GPR52 (0.55) GPR52KLKB1TP53SMN1; SMN2HPGD
SCHEMBL1850607 0.88 GPR52 (0.52) GPR52KLKB1TP53SMN1; SMN2KMT2A
SCHEMBL1849196 0.88 GPR52 (0.52) GPR52KLKB1SMN1; SMN2HPGDALDH1A1
SCHEMBL1849364 0.88 GPR52 (0.51) GPR52SMN1; SMN2ALDH1A1JMJD6ELANE
SCHEMBL1851194 0.87 GPR52 (0.70) GPR52SMN1; SMN2KMT2AHPGDMEN1
SCHEMBL1851300 0.86 GPR52 (0.47) GPR52KLKB1SMN1; SMN2ALDH1A1JMJD6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2323978-A1 AMIDE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2011-05-25 EP disclosed
WO-2010018874-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-02-18 WO disclosed
US-20100041891-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-02-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041891-A1 AMIDE COMPOUND GPR52, GPR132, NR5A2 GPR52 1/4885KLKB1 4616/4885TP53 3403/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.